Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
Recruiting
N/A
Interventional Study
Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation
Hematologic Disorders
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 45 (estimated)
- Sponsor
- The General Hospital of Western Theater Command · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Participants must meet the following criteria:
1. The patient signed an informed consent form and voluntarily participated in the study.
2. Patients undergoing HLA haploidentical allogeneic hematopoietic stem cell transplantation;
3. Age ≥18 years, regardless of gender
4. ECOG …
Contacts